0GWJ Stock Chart & Stats
€46.80
€0.40(1.22%)
At close: 4:00 PM EST
€46.80
€0.40(1.22%)
Day’s Range― - ―
52-Week Range€40.20 - €62.00
Previous CloseN/A
Volume1.00
Average Volume (3M)232.00
Market Cap
€867.34M
Enterprise Value€882.45M
Total Cash (Recent Filing)€51.59M
Total Debt (Recent Filing)€9.90M
Price to Earnings (P/E)19.1
Beta0.52
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.79
Shares Outstanding16,307,580
10 Day Avg. Volume88
30 Day Avg. Volume232
Financial Highlights & Ratios
PEG Ratio2.92
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€71.50Price Target Upside52.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.86
Revenue Forecast (FY)€331.00M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthThe sustained increase in revenue indicates expanding demand for Clinica Baviera’s ophthalmology services across its clinic network. Continued top-line growth supports operating leverage, provides resources for clinic investment, and strengthens the company’s ability to compound earnings over the next several quarters.
Strong ProfitabilityConsistently strong net margins show that the company converts clinical service revenue into meaningful earnings across reporting periods. This profitability provides resilience, supports reinvestment in its operating network, and gives management flexibility to pursue growth without relying solely on external financing.
Healthy Cash GenerationOperating cash flow consistently exceeding net income supports the quality of reported earnings and indicates effective cash realization from operations. Positive and improving free cash flow also strengthens the company’s capacity to fund investment, reduce debt, and support future shareholder returns.
Bears Say
Margin VolatilityRecent changes in gross and operating margins introduce uncertainty around how durable the company’s current profitability is. If the movement reflects cost or pricing pressure rather than temporary mix effects, continued margin volatility could limit earnings growth even while revenue remains positive.
Moderate Free-Cash-Flow ConversionAlthough free cash flow remains positive, only moderate conversion from net income means reported profits do not consistently become available cash at the same rate. Ongoing reinvestment needs or working-capital movements could constrain debt reduction, capital returns, and internally funded expansion.
Deleveraging DurabilityThe recent balance-sheet improvement is a clear strength, but historically elevated leverage means its durability still matters to the investment case. If the latest debt reduction reflects timing rather than a structural change, financial flexibility could prove less durable during expansion or weaker operating conditions.
Clinica Baviera News
0GWJ FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest share price was €40.20 and its highest was €62.00 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €867.34M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Nov 05, 2026 which is in 5 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Jul 29, 2026. The company reported €0.747 earnings per share for the quarter.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Undervalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA does not currently pay dividends.
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.747 in its last earnings report. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in GB:0GWJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a medical company, provides ophthalmologic medicine services in Spain, Germany, and rest of Europe. The company offers refractive, presbyopia, and cataract surgeries; and oculoplastia, corneal disease, dry eye, strabismus, pediatric ophthalmology, glaucoma, neuro-ophthalmological, disorders, and blepharoplasty treatments. It also provides external and internal consultations, surgery treatments, and rehabilitation services. The company was formerly known as Clínica Oftalmológica Baviera, S.L. and changed its name to Clínica Baviera, S.A. in 2000. Clínica Baviera, S.A. was incorporated in 1992 and is based in Madrid, Spain. Clínica Baviera, S.A. is a subsidiary of Aier Eye International (Europe), S.L.U.
0GWJ Stock 12 Month Forecast
Average Price Target
€71.50
▲(52.78% Upside)